Development of a technology for expression of recombinant human erythropoietin in cultured mammalian cells using alphavirus expression system

Currently there are no industrial eukaryotic expression systems other than transient expression from plasmids or expression from genes integrated into host genome. Both approaches (use of eukaryotic plasmids or chromosomal integration) suffer from poor scalability and often from poor yields. Although, in laboratory settings, effective means for transducing of cultured cells to express foreign proteins and for high-level transient expression were developed based on viral genomes. We thought to develop a scalable and suitable for industrial application technology for the production of recombinant human erythropoietin (EPO) in mammalian cell cultures using an expression vector based on the genome of RNA virus

Development of a technology for expression of recombinant human erythropoietin in cultured mammalian cells using alphavirus expression system

Currently there are no industrial eukaryotic expression systems other than transient expression from plasmids or expression from genes integrated into host genome. Both approaches (use of eukaryotic plasmids or chromosomal integration) suffer from poor scalability and often from poor yields. Although, in laboratory settings, effective means for transducing of cultured cells to express foreign proteins and for high-level transient expression were developed based on viral genomes. We thought to develop a scalable and suitable for industrial application technology for the production of recombinant human erythropoietin (EPO) in mammalian cell cultures using an expression vector based on the genome of RNA virus

Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study.

We evaluated the associations between single nucleotide polymorphisms and different clinical parameters related to type 2 diabetes mellitus (T2DM), obesity risk, and metabolic syndrome (MS) in a Kazakh cohort. A total of 1336 subjects, including 408 T2DM patients and 928 control subjects, were recruited from an outpatient clinic and genotyped for 32 polymorphisms previously associated with T2DM and obesity-related phenotypes in other ethnic groups. For association studies, the chi-squared test or Fisher's exact test for binomial variables were used. Logistic regression was conducted to explore associations between the studied SNPs and the risk of developing T2DM, obesity, and MS, after adjustments for age and sex. After excluding four SNPs due to Hardy-Weinberg disequilibrium, significant associations in age-matched cohorts were found betweenT2DM and the following SNPs: rs9939609 (FTO), rs13266634 (SLC30A8), rs7961581 (TSPAN8/LGR5), and rs1799883 (FABP2). In addition, examination of general unmatched T2DM and control cohorts revealed significant associations between T2DM and SNPsrs1799883 (FABP2) and rs9939609 (FTO). Furthermore, polymorphisms in the FTO gene were associated with increased obesity risk, whereas polymorphisms in the FTO and FABP2 genes were also associated with the risk of developing MS in general unmatched cohorts. We confirmed associations between polymorphisms within the SLC30A8, TSPAN8/LGR5, FABP2, and FTO genes and susceptibility to T2DM in a Kazakh cohort, and revealed significant associations with anthropometric and metabolic traits. In particular, FTO and FABP2 gene polymorphisms were significantly associated with susceptibility to MS and obesity in this cohort

Split core technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE

Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule

Development of a recombinant foot -and-mouth disease vaccine

Foot-and-mouth disease (FMD) is important disease of cloven-foot animals including cows and swine. Although annual vaccination against the FMD is mandated in regions of South Kazakhstan, outbreaks of the disease are registered every year. These outbreaks result in huge economic losses because international rules require culling of all the diseased and contacted animals and all products from these animals must be destroyed. Currently available anti-FMD vaccines are all produced using the original technology of inactivation of virus (foot-and-mouth disease virus, FMDV) grown in cell cultures. Recombinant anti-FMD vaccine is a long anticipated development in the industry because the recombinant vaccine is safe and compatible with diagnostic tests for discrimination of diseased and vaccinated animals (DIVA)

Development of a recombinant foot -and-mouth disease vaccine

Foot-and-mouth disease (FMD) is important disease of cloven-foot animals including cows and swine. Although annual vaccination against the FMD is mandated in regions of South Kazakhstan, outbreaks of the disease are registered every year. These outbreaks result in huge economic losses because international rules require culling of all the diseased and contacted animals and all products from these animals must be destroyed. Currently available anti-FMD vaccines are all produced using the original technology of inactivation of virus (foot-and-mouth disease virus, FMDV) grown in cell cultures. Recombinant anti-FMD vaccine is a long anticipated development in the industry because the recombinant vaccine is safe and compatible with diagnostic tests for discrimination of diseased and vaccinated animals (DIVA)

Split core technology allows efficient production of virus-like particles presenting a receptor-contacting epitope of human IgE

Immunoglobulin E (IgE) plays a central role in type I hypersensitivity including allergy and asthma. Novel treatment strategy envisages development of a therapeutic vaccine designed to elicit autologous blocking antibodies against the IgE. We sought to develop an IgE-epitope antigen that induces antibodies against a receptor-contacting epitope on human IgE molecule